The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study
Clin Gastroenterol Hepatol. 2022 Feb 17;S1542-3565(22)00179-3.doi: 10.1016/j.cgh.2022.01.059. Online ahead of print.
1Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI. Electronic address: aslok@med.umich.edu.
2Johns Hopkins University School of Medicine, Baltimore, MD.
3University of Cincinnati College of Medicine, Cincinnati, OH.
4University of California San Francisco, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA.
5Medstar Health Research Institute, Washington, DC.
6University of Pennsylvania, Philadelphia, PA.
Abstract
Multiple real-world studies have confirmed the safety and efficacy of hepatitis C (HCV) direct-acting antivirals (DAAs); however, few studies have provided data on long-term outcomes of patients without cirrhosis after achieving sustained virologic response (SVR).1-3 The aims of this analysis were to describe, among individuals in the PRIORITIZE Study achieving SVR: (1) the frequency of laboratory testing and imaging during long-term follow-up (LTFU), (2) changes in liver tests, (3) occurrence of hepatic decompensation or hepatocellular carcinoma (HCC) and deaths, and (4) durability of SVR.